Remove tag security
article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

In its October 28 quarterly Securities and Exchange Commission (SEC) filing, the company said that Roctavian’s commercial launch is now underway. million price tag. The post Can gene therapies for haemophilia defend their high price tags? BioMarin previously said that the treatment’s European price would likely be around EUR1.5

111
111
article thumbnail

NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta

pharmaphorum

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. . The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year.

Hospitals 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How automation can help to address supply chain challenges in pharma

pharmaphorum

Fully integrated and automated ingredient to consumer batch tracking using barcoding, RFID tagging, or IoT temperature logging and timestamping significantly reduces the chance of these mix-ups, providing complete traceability records from ingredient manufacturer to patient, and ensures the safety of the product.

article thumbnail

Fidelis Specialty Pharmacy Selects Citus Health to Enable Real-Time Virtual Patient Communications and Faster Collection of Key Patient Data

Citus Health Specialty Pharmacy

Fidelis will also leverage Citus Health for real-time referral, refill production and delivery workflows that allow them to prioritize and track efficiency efforts with customizable forms, App-Less electronic signatures for signed refill and delivery consent and messaging to tag and track key patient data.

article thumbnail

Apellis set to take on Alexion as FDA clears PNH drug Empaveli

pharmaphorum

Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) – with a label that will allow it to challenge Alexion’s established therapies directly. . billion and $1.1

article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

This evolution is leading to additional health benefits and health gains, but they are accompanied by major concerns, as very high price tags raise questions about their affordability.”. In recent years, revolutionary medicines have come with price tags to match, but this is simply a symptom of our current model.

article thumbnail

Citus Health Announces Groundbreaking Home Healthcare Consumer Research

Citus Health Specialty Pharmacy

Providers can improve the patient and family caregiver experience through real-time communication technology such as role-based auto-escalation algorithms for inbound communication and secure instant messaging. ” What do Home Healthcare Consumers Say? . ” What do Home Healthcare Consumers Say?